Skip to content
Supreme Club Zone

Individuals Stopping Slimming Injections Gain Back Weight at a Quadrupled Rate Than Those on Conventional Diets

Illustration of pharmaceutical injection and weighing machine
Obesity treatment often requires ongoing approaches.

New research reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional diet and exercise regimens.

Findings released in a leading health publication points out that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.

"Users using these drugs must be cognizant of the danger of rapid rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.

Such speed of regain implies a reversion to starting mass within about a year and a half.

Comparing Treatments

The study, which reviewed 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.

The team note that individuals who lose weight through dieting typically have a more gradual creep back—approximately 0.1 kg a month—once they finish.

Understanding the Fast Regain

Nutrition scientists believe the mechanism of the jabs is key to understanding the accelerated rebound.

The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.

"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.

"Stopping of this medication means hunger is unsuppressed, making excessive eating a significant risk."

An Ongoing Issue?

Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.

A number of clinicians argue that, given the likelihood of weight regain, the therapy is often life-long.

This view is reinforced by pharmaceutical companies, who say that the results "highlight the persistent character of obesity," akin to managing diseases like diabetes.

User Testimonies

Individuals who have stopped the jabs describe a sudden return of appetite.

"It felt as if a trigger activating and I was suddenly ravenous," said one woman.

The struggle is compounded if patients have not developed lasting dietary or behavioural modifications during treatment.

Widespread Use

Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.

  • Adoption is more common among females than males.
  • The 40s and 50s demographic shows the greatest level of interest.
  • Many obtain the drugs through private prescriptions rather than public health services.

Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and long-term success likely depends on ongoing behavioural changes.

GE
About the author

Gloria Elliott

A fashion journalist with over a decade of experience covering luxury brands and global lifestyle trends.

Supreme Club Zone

Type to search articles.